Director Christopher D. Payne filed a Form 4 with the SEC on November 17, 2026, disclosing the acquisition of 810 restricted stock units in Hims & Hers Health, Inc. (NYSE:HIMS) on November 13, 2026, issued in lieu of his cash director retainer fee for the third quarter of 2026.

Key Highlights

  • Transaction date: 810 RSUs were acquired on November 13, 2026, via transaction code M (conversion of derivative security).
  • Retainer in lieu of cash: The RSUs were issued under the company's Director Compensation Policy in place of the Q3 2026 cash retainer fee of $23,125.
  • Grant price: The RSU count was calculated by dividing $23,125 by a grant price of $28.53 per share.
  • Vesting schedule: According to the filing, the RSUs will vest in full on the company's next quarterly vesting date.
  • Direct holdings after transaction: Payne directly holds 35,673 shares of Class A Common Stock following the reported transaction.
  • Indirect holdings: An additional 110,000 shares are held indirectly through The Payne Family Trust dtd 09/17/2020.

Christopher Payne's Q3 2026 RSU Grant at Hims & Hers Health

According to the filing, Christopher D. Payne, a director of Hims & Hers Health, Inc. (NYSE:HIMS), received 810 restricted stock units on November 13, 2026. The RSUs were granted pursuant to the issuer's Director Compensation Policy and represent a contingent right to receive one share of Class A Common Stock per RSU. The filing states the RSUs were issued "in lieu of the director retainer fee for the third quarter of 2026," with the unit count derived by dividing foregone cash fees of $23,125 by the grant price of $28.53.

The derivative security carried a price of $0 and was converted on the same date it was granted, recorded under transaction code M. Following the transaction, Payne directly owns 35,673 shares of Class A Common Stock. He also holds 110,000 shares indirectly through The Payne Family Trust dtd 09/17/2020, according to the filing. The RSUs have a remaining balance of zero derivative securities after the conversion, as reported in Table II.

The Form 4 was signed by Kimberly Mather as Attorney-in-Fact for Christopher D. Payne and filed on November 17, 2026. No amendment date is indicated, and the filing was submitted by one reporting person. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan.

What Was Disclosed

Hims & Hers Health director Christopher D. Payne disclosed the conversion of 810 RSUs into Class A Common Stock on November 13, 2026, issued in place of a $23,125 Q3 2026 retainer fee at a grant price of $28.53, leaving him with 35,673 directly held shares.